Tanespimycin (17-AAG)

For research use only.

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

68 publications

Tanespimycin (17-AAG) Chemical Structure

CAS No. 75747-14-7

Tanespimycin (17-AAG, CP127374, NSC-330507, KOS 953) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Tanespimycin (17-AAG) induces apoptosis, necrosis, autophagy and mitophagy. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 287 In stock
USD 97 In stock
USD 297 In stock
USD 797 In stock
USD 1337 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Tanespimycin (17-AAG) has been cited by 68 publications

Purity & Quality Control

Choose Selective HSP (HSP90) Inhibitors

Biological Activity

Description Tanespimycin (17-AAG, CP127374, NSC-330507, KOS 953) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Tanespimycin (17-AAG) induces apoptosis, necrosis, autophagy and mitophagy. Phase 3.
Features Displays very low toxicity toward normal cells.
Targets
HSP90 [1]
(Cell-free assay)
5 nM
In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. [1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. [2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NFPGbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYf3TlRPUUN3ME2wMlAxODNyMzFOwG0> M1u1dXNCVkeHUh?=
IST-MEL1 NUnRXGFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwMECwOFA4KM7:TR?= NWLjV5Y3W0GQR1XS
NCI-SNU-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LJe2lEPTB;MD6wNFIxPyEQvF2= NVvEWplZW0GQR1XS
FADU M17FNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;lfmdtUUN3ME2wMlAxOjB7IN88US=> NWjWN2lGW0GQR1XS
C32 NE\1NHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXizb4pHUUN3ME2wMlAxOzB2IN88US=> MVzTRW5ITVJ?
D-566MG NVjsVlB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fzbGlEPTB;MD6wNFM6KM7:TR?= NIfOdVRUSU6JRWK=
LXF-289 NWDm[ot4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXFXoRKSzVyPUCuNFA1OTlizszN MkDQV2FPT0WU
HGC-27 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLETWM2OD1yLkCwOVEh|ryP M3vIVHNCVkeHUh?=
RPMI-7951 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwMEC3NVch|ryP NVHie|VyW0GQR1XS
HSC-3 NIjqcmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTyTWM2OD1yLkCwPVI6KM7:TR?= MVnTRW5ITVJ?
MIA-PaCa-2 MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWT5ZnpZUUN3ME2wMlAyODB7IN88US=> MYnTRW5ITVJ?
KS-1 NV\KRYlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDHRm1yUUN3ME2wMlAyOzV3IN88US=> NVPVbJBNW0GQR1XS
CAL-51 NYLacGRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\TXJlKSzVyPUCuNFE1ODVizszN NXfvbYZLW0GQR1XS
MDA-MB-361 MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkP3TWM2OD1yLkCxOFk2KM7:TR?= M1LiOXNCVkeHUh?=
TI-73 NXPyfG5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYewU41FUUN3ME2wMlAyPzl4IN88US=> M1\Q[XNCVkeHUh?=
AGS NHjQd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwMEG5N|gh|ryP M1vDeHNCVkeHUh?=
NCI-H460 NWDH[pU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMEG5O|Qh|ryP NHPjVoNUSU6JRWK=
A204 MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPp[mpKSzVyPUCuNFIzPDlizszN NHW2bFdUSU6JRWK=
CHL-1 Mom0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnG1TWM2OD1yLkCyNlUyKM7:TR?= MXvTRW5ITVJ?
DU-4475 NInveJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjOS2dTUUN3ME2wMlAzOjZzIN88US=> MUXTRW5ITVJ?
CGTH-W-1 M3jGdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX74fmpSUUN3ME2wMlAzOzR7IN88US=> NVvidGd2W0GQR1XS
HCC2218 MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zQc2lEPTB;MD6wNlQ6PCEQvF2= MVzTRW5ITVJ?
A2780 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYW1XHFlUUN3ME2wMlAzPTNzIN88US=> Mnz3V2FPT0WU
NCI-H720 NWfFb3ppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HLU2lEPTB;MD6wNlU1PiEQvF2= MWPTRW5ITVJ?
NCI-N87 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwMEK1PVMh|ryP NEnWfo5USU6JRWK=
CHP-212 NXnQdFNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfB[HBKUUN3ME2wMlAzPjJ6IN88US=> M4fqbXNCVkeHUh?=
NCI-H23 NUe3cVN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLFTWM2OD1yLkCyOlY2KM7:TR?= NW\hTFFrW0GQR1XS
D-263MG M1HBSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\TTmNpUUN3ME2wMlAzPzh4IN88US=> Mlv0V2FPT0WU
ME-180 NEjsT|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFG5OXRKSzVyPUCuNFI5QTFizszN NI\CO3JUSU6JRWK=
SW982 NX\kNo9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwMEK5PVkh|ryP Mn3zV2FPT0WU
OE19 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LlZmlEPTB;MD6wN|A4PyEQvF2= NIDBTHNUSU6JRWK=
SK-LU-1 NYrNRWhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7LO5ZoUUN3ME2wMlA{ODh{IN88US=> MnjKV2FPT0WU
H4 M3zwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\VWndtUUN3ME2wMlA{ODlizszN NXPTUopmW0GQR1XS
HT-144 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\rUGlEPTB;MD6wN|A6OyEQvF2= NXfZS|RLW0GQR1XS
SK-UT-1 NFmwPHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwMEOxO|gh|ryP MWrTRW5ITVJ?
D-336MG M1L4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwMEOzNFkh|ryP NX7yelZnW0GQR1XS
MDA-MB-175-VII NF3MOI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwMEOzOVQh|ryP MnHNV2FPT0WU
GAMG M3Hn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrj[XNKSzVyPUCuNFM1OzVizszN MVTTRW5ITVJ?
CP50-MEL-B NFjjR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TNOmlEPTB;MD6wN|Q2KM7:TR?= MXLTRW5ITVJ?
OVCAR-5 Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3wTWM2OD1yLkCzOFgh|ryP NELpfZZUSU6JRWK=
SK-MES-1 M2nnS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvhTWM2OD1yLkCzOlA3KM7:TR?= NXPMV5pWW0GQR1XS
VM-CUB-1 MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID5cmhKSzVyPUCuNFM3PTdizszN MkP0V2FPT0WU
WM-115 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjBO|Z5UUN3ME2wMlA{PzZ{IN88US=> NF60Um9USU6JRWK=
DSH1 MnHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TCZWlEPTB;MD6wN|gxPyEQvF2= NYnWcIt6W0GQR1XS
Becker NYDJ[mVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwMEO4PFUh|ryP MmfXV2FPT0WU
SW962 M33SXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMEO5OFUh|ryP MnXtV2FPT0WU
TYK-nu NF\2elRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorpTWM2OD1yLkCzPVg2KM7:TR?= MX3TRW5ITVJ?
HO-1-N-1 M{jafGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfWTWM2OD1yLkC0NFIyKM7:TR?= NUnrOVJ1W0GQR1XS
T98G MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojlTWM2OD1yLkC0NVA{KM7:TR?= M37B[HNCVkeHUh?=
ACN NXnTcnJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXhV3lKSzVyPUCuNFQyPjJizszN M3zGUHNCVkeHUh?=
SW780 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfYfYM1UUN3ME2wMlA1OjB|IN88US=> MmPtV2FPT0WU
Detroit562 M3\qbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwMESyN|kh|ryP NUPEdFFMW0GQR1XS
BB49-HNC NWrWRmpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITtZ3FKSzVyPUCuNFQzPDNizszN MkKzV2FPT0WU
HN MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M161PGlEPTB;MD6wOFI4OiEQvF2= M1zSXHNCVkeHUh?=
H9 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzSZ5k6UUN3ME2wMlA1OzdzIN88US=> NWnCSGliW0GQR1XS
VA-ES-BJ MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zOR2lEPTB;MD6wOFQ1PyEQvF2= NHjlW2NUSU6JRWK=
MEL-JUSO NVPpeZl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;kWWlEPTB;MD6wOFQ4PSEQvF2= MorKV2FPT0WU
BT-474 NVzFOJZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jKeGlEPTB;MD6wOFUh|ryP M1nvT3NCVkeHUh?=
CaR-1 NEfaPIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7uUmFwUUN3ME2wMlA1PTR7IN88US=> M1vkd3NCVkeHUh?=
PSN1 NHPTelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwMES2NFMh|ryP MV;TRW5ITVJ?
KYSE-510 NXXybnlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMES2OFkh|ryP MWHTRW5ITVJ?
KP-4 NFm3dFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFOzXWxKSzVyPUCuNFQ4PTNizszN NWntNZRpW0GQR1XS
KYSE-410 MnzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;ENGlKSzVyPUCuNFQ4PzJizszN M4m4WnNCVkeHUh?=
G-402 NXzDbGVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHoSFNKSzVyPUCuNFQ4QDlizszN Mon4V2FPT0WU
DOK M2jKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLwTWM2OD1yLkC0PVAzKM7:TR?= NFnISWxUSU6JRWK=
COR-L88 MkXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXG0eFZNUUN3ME2wMlA1QTF{IN88US=> NV3NOXZkW0GQR1XS
SKG-IIIa MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HwcGlEPTB;MD6wOFk5PiEQvF2= MXXTRW5ITVJ?
AN3-CA MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwMEWg{txO NXq1cmpOW0GQR1XS
SW48 MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwMEWwN|kh|ryP MoTOV2FPT0WU
YKG-1 NELQVVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\IVpJlUUN3ME2wMlA2ODdzIN88US=> NI[1[HlUSU6JRWK=
KYSE-150 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXlRVlKSzVyPUCuNFUzOzVizszN NF7pS5FUSU6JRWK=
HuO-3N1 MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMEWyN|ch|ryP MX\TRW5ITVJ?
LB1047-RCC NG\yZ2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfrSZFKSzVyPUCuNFUzQTZizszN M{HMcHNCVkeHUh?=
NCI-H2030 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTWOZR4UUN3ME2wMlA2PDF2IN88US=> NHjuUXVUSU6JRWK=
YH-13 Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPNTWM2OD1yLkC1O|IzKM7:TR?= MYTTRW5ITVJ?
5637 NF\2PFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELx[nhKSzVyPUCuNFU4PCEQvF2= M2TIPXNCVkeHUh?=
LOXIMVI M3K4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfLUVNKSzVyPUCuNFU5PzJizszN M2jZbnNCVkeHUh?=
GT3TKB M1LaT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHxTWM2OD1yLkC1PVQzKM7:TR?= NXHEUVFTW0GQR1XS
TCCSUP NFPOfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4q3OmlEPTB;MD6wOVk3PCEQvF2= M{K1cnNCVkeHUh?=
EPLC-272H NGj1UGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwME[yNFUh|ryP NX;WW3lZW0GQR1XS
LU-99A MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HLZWlEPTB;MD6wOlI{PyEQvF2= MWHTRW5ITVJ?
NCI-H1755 M17XfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3S3ZWlEPTB;MD6wOlM1OSEQvF2= M2n6WnNCVkeHUh?=
KM12 NWnTenM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13DNmlEPTB;MD6wOlM1QCEQvF2= M2rQWHNCVkeHUh?=
SF295 NF:xXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4O0TGlEPTB;MD6wOlQ2OiEQvF2= NEjjNpBUSU6JRWK=
MZ2-MEL MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwME[1OVMh|ryP MVnTRW5ITVJ?
HEC-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTBwME[1PFgh|ryP MX;TRW5ITVJ?
SW684 MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LabmlEPTB;MD6wOlU6OSEQvF2= M4X3bHNCVkeHUh?=
SF539 NFnaW4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwME[2PFEh|ryP MUTTRW5ITVJ?
GMS-10 MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37pbWlEPTB;MD6wOlY6QSEQvF2= NV71Z2lnW0GQR1XS
MV-4-11 NEXjVplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwME[4NFMh|ryP MUPTRW5ITVJ?
HT-29 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vTWGlEPTB;MD6wOlkyQSEQvF2= MVjTRW5ITVJ?
23132-87 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDtSItKSzVyPUCuNFY6PSEQvF2= NYC3PY5bW0GQR1XS
SW620 MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3W3eWlEPTB;MD6wO|AzPiEQvF2= MYnTRW5ITVJ?
HCC1806 NEX6RWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HUXmlEPTB;MD6wO|E{OSEQvF2= M3HtcXNCVkeHUh?=
Hs-578-T MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13iZmlEPTB;MD6wO|IxQCEQvF2= M{XhOXNCVkeHUh?=
A2058 M{fKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjEcXkzUUN3ME2wMlA4OjJ6IN88US=> NFm0VFdUSU6JRWK=
MEL-HO NYPpcox2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPnNmFKSzVyPUCuNFczPTVizszN M4HIPXNCVkeHUh?=
HCC2998 NYC3e5ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwMEezOFch|ryP M{PXSnNCVkeHUh?=
HuO9 NV20[mlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofhTWM2OD1yLkC3OVg6KM7:TR?= NVzHVoVLW0GQR1XS
CAL-39 MkT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1n5U2lEPTB;MD6wO|c3PiEQvF2= NFLXO|JUSU6JRWK=
M14 MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\XRmlEPTB;MD6wO|kyOyEQvF2= M1TSTnNCVkeHUh?=
BFTC-909 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPMSWpKSzVyPUCuNFc6PjlizszN MUfTRW5ITVJ?
TE-11 NXfWOIJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojlTWM2OD1yLkC3PVk3KM7:TR?= NX7QV2dxW0GQR1XS
TGBC1TKB MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXLcZRKSzVyPUCuNFgxPDNizszN MXLTRW5ITVJ?
L-363 NX\qb5o4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;iclR3UUN3ME2wMlA5OjB4IN88US=> NIfHeI9USU6JRWK=
A431 M2fHb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDSTWM2OD1yLkC4NlEh|ryP MVrTRW5ITVJ?
MKN45 M{GwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPx[2hYUUN3ME2wMlA5OjF7IN88US=> NF3sOJVUSU6JRWK=
HT-1080 M1nkOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDBVWRKSzVyPUCuNFg1OzlizszN M{TuXXNCVkeHUh?=
OVCAR-8 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXn1NZZEUUN3ME2wMlA5PjJ{IN88US=> Mn7YV2FPT0WU
LCLC-97TM1 NH60NWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Ttb2lEPTB;MD6wPFczQCEQvF2= Mlr1V2FPT0WU
M059J MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwMEmwNlch|ryP M2[1T3NCVkeHUh?=
SK-MEL-2 M1nLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGH0N|dKSzVyPUCuNFkxPiEQvF2= MknGV2FPT0WU
TE-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlX3TWM2OD1yLkC5NlA1KM7:TR?= MWTTRW5ITVJ?
KYSE-180 M4njcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMEmyOlIh|ryP MWrTRW5ITVJ?
D-247MG NFfrOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMEm0OVUh|ryP NV;heVVbW0GQR1XS
8-MG-BA MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPiNoZKSzVyPUCuNFk1PzJizszN NUnCcoQyW0GQR1XS
NCI-H1792 Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTSTWM2OD1yLkC5OlE5KM7:TR?= MV;TRW5ITVJ?
MCF7 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LNR2lEPTB;MD6wPVY4PyEQvF2= MXLTRW5ITVJ?
NCI-H2122 NF;H[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;STWM2OD1yLkC5O|Q2KM7:TR?= M{fwNHNCVkeHUh?=
EFO-27 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMEm5PVch|ryP Mof5V2FPT0WU
LB2241-RCC M{\VcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwMUCwOVQh|ryP M2PWOXNCVkeHUh?=
SN12C M1nUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwMUCxNFch|ryP MkfRV2FPT0WU
A498 NUfLWXAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwMUCxPEDPxE1? NHTNOJFUSU6JRWK=
PANC-03-27 NIHifWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvnOJBKSzVyPUCuNVAzQDZizszN MmXoV2FPT0WU
NCI-H1581 NVjGWIxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjqTWM2OD1yLkGwNlkh|ryP NYfIO3NvW0GQR1XS
U-87-MG M3H4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rBNGlEPTB;MD6xNFMxPyEQvF2= MYrTRW5ITVJ?
G-401 MnHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPFTWM2OD1yLkGwN|U{KM7:TR?= NHL2[lhUSU6JRWK=
SiHa NXrCUnhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMUC0PFYh|ryP NGTleXpUSU6JRWK=
U251 NITpeXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4izbWlEPTB;MD6xNFUzPSEQvF2= MXPTRW5ITVJ?
MMAC-SF MoThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1X5OmlEPTB;MD6xNFU{OSEQvF2= M37BPHNCVkeHUh?=
BB65-RCC MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnT1TWM2OD1yLkGwOVU1KM7:TR?= MU\TRW5ITVJ?
NKM-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvZZ5JKSzVyPUCuNVA3PjZizszN NETwclVUSU6JRWK=
HD-MY-Z NIrjU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnhTWM2OD1yLkGwPFc{KM7:TR?= M3f3SXNCVkeHUh?=
TGBC11TKB M4XGSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXOzVGVwUUN3ME2wMlExQTB|IN88US=> MmTXV2FPT0WU
COLO-679 MnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMUGyNVEh|ryP NHLhN5RUSU6JRWK=
TE-8 MnvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K3V2lEPTB;MD6xNVI3PCEQvF2= NXTXbnFkW0GQR1XS
SK-MEL-28 M1jEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMUGzNlEh|ryP M2nV[HNCVkeHUh?=
SH-4 NX\NOHJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLSTWM2OD1yLkGxN|U3KM7:TR?= M2nK[XNCVkeHUh?=
KALS-1 NYTlcYVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULkVpBXUUN3ME2wMlEyOzl|IN88US=> MkfwV2FPT0WU
RKO MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTscmd6UUN3ME2wMlEyPzZ2IN88US=> MYnTRW5ITVJ?
OMC-1 M{XHdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXLSFBKSzVyPUCuNVE4QTdizszN NFHVTFBUSU6JRWK=
BT-549 NIrNNYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwMUG3PVkh|ryP MmDvV2FPT0WU
NCI-H28 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMUG4NVch|ryP MX;TRW5ITVJ?
RXF393 NX;yVIhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjIW|h6UUN3ME2wMlEyQTh{IN88US=> NULtT5J4W0GQR1XS
COLO-829 M1P0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[2[4pKSzVyPUCuNVIxODVizszN NFPnZWZUSU6JRWK=
HMV-II Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXKWlBqUUN3ME2wMlEzODJizszN NIfTZWZUSU6JRWK=
SW1990 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMUKxOVch|ryP M1nLW3NCVkeHUh?=
NCI-H1437 MkTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml32TWM2OD1yLkGyNVU4KM7:TR?= MWnTRW5ITVJ?
SNB75 NVvE[ol2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlH0TWM2OD1yLkGyNVY6KM7:TR?= M3fRV3NCVkeHUh?=
EW-3 Mn7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwMUK2OlEh|ryP MWTTRW5ITVJ?
SAS MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PjW2lEPTB;MD6xNlY6KM7:TR?= NUnWZnd3W0GQR1XS
NCI-H1666 MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\PTWM2OD1yLkGyO|c1KM7:TR?= M1y0SnNCVkeHUh?=
A375 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTtTWM2OD1yLkGyO|c5KM7:TR?= MVvTRW5ITVJ?
CAMA-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\zb2tKUUN3ME2wMlEzQTJ2IN88US=> NELoS4JUSU6JRWK=
HuP-T4 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK0d4hKSzVyPUCuNVI6PDNizszN MoOwV2FPT0WU
NCI-H292 NVr5[YtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMUOxNUDPxE1? NHr3[JFUSU6JRWK=
PC-14 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2T5V2lEPTB;MD6xN|IyOSEQvF2= M3\MNnNCVkeHUh?=
BPH-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXj3VYRIUUN3ME2wMlE{PDFizszN NX7xd2xoW0GQR1XS
GAK MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mli0TWM2OD1yLkGzOVY4KM7:TR?= M4DybXNCVkeHUh?=
VMRC-RCZ MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwMUO3OlIh|ryP MkPhV2FPT0WU
SK-MEL-24 NV63UIdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoX6TWM2OD1yLkGzPFch|ryP MWDTRW5ITVJ?
LB831-BLC NVn6fmdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMUO4PFMh|ryP NXj5OIs6W0GQR1XS
NCI-H2452 NETNdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwMUO5OVYh|ryP Mn\xV2FPT0WU
RT-112 MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPoUIRKSzVyPUCuNVQxOzVizszN Moi3V2FPT0WU
GP5d NF\MbJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwMUSxNFQh|ryP MXHTRW5ITVJ?
LC-2-ad NUmz[JoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfUfGFKSzVyPUCuNVQyOjFizszN M3ntT3NCVkeHUh?=
MPP-89 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fUN2lEPTB;MD6xOFEzPSEQvF2= MkDKV2FPT0WU
NUGC-3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nyUGlEPTB;MD6xOFQ4QCEQvF2= MkfBV2FPT0WU
GI-1 M{HIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\VWZVCUUN3ME2wMlE1PTV6IN88US=> NXrLRZE2W0GQR1XS
HCC1419 Mn\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMUS1O|Yh|ryP NXvOW3F2W0GQR1XS
SW1573 Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfsc5I1UUN3ME2wMlE1PzV6IN88US=> M1O2OnNCVkeHUh?=
NCI-H2347 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnqzTWM2OD1yLkG0PFM6KM7:TR?= M4LDcnNCVkeHUh?=
Mewo NVHwZ4dET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPIdpRuUUN3ME2wMlE1QDh7IN88US=> Mn7tV2FPT0WU
639-V M{f6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTi[INKSzVyPUCuNVUxOTNizszN NX31bGJsW0GQR1XS
AsPC-1 MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TE[WlEPTB;MD6xOVIzPSEQvF2= MUnTRW5ITVJ?
NCI-H1648 MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\hbItKSzVyPUCuNVUzOzJizszN NI[4S|hUSU6JRWK=
786-0 NI\QO3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETaWGhKSzVyPUCuNVU{QDFizszN NFvLR4FUSU6JRWK=
ETK-1 NY\1[W9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPEOYFKSzVyPUCuNVU6KM7:TR?= Mo[3V2FPT0WU
BxPC-3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUS1SHNPUUN3ME2wMlE2QTZ4IN88US=> NGTo[IhUSU6JRWK=
CAL-62 M2TxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMU[xOlkh|ryP NUnINYh1W0GQR1XS
HCC1937 MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{D3W2lEPTB;MD6xOlI4PSEQvF2= MkfyV2FPT0WU
NCI-H1299 M1qxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXn1TnpVUUN3ME2wMlE3Ojh3IN88US=> MnPEV2FPT0WU
SW1088 Ml;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwMU[0NVMh|ryP NWnyOWtGW0GQR1XS
FTC-133 M3vuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PUU2lEPTB;MD6xOlU1KM7:TR?= NVLnSoJTW0GQR1XS
OC-314 NVLROFB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGS2VXNKSzVyPUCuNVY3QSEQvF2= NV65eGtZW0GQR1XS
SCC-9 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2P1PGlEPTB;MD6xOlcyPiEQvF2= MmXMV2FPT0WU
HT-1376 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMU[5N|Yh|ryP MoDSV2FPT0WU
U-2-OS NX3LelVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMUexO|Mh|ryP NFS3VG1USU6JRWK=
COLO-824 M{jN[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnSU4FKSzVyPUCuNVczQTRizszN MmSwV2FPT0WU
BB30-HNC NVXwUZpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEOydJpKSzVyPUCuNVc{OyEQvF2= MnmyV2FPT0WU
NCI-H2087 MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDzOJZKSzVyPUCuNVc{PjhizszN MmLqV2FPT0WU
NCI-H2170 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjZZnYyUUN3ME2wMlE4PTN4IN88US=> M1TYOnNCVkeHUh?=
SK-OV-3 NFHjSJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYL3ZZRYUUN3ME2wMlE4PTdzIN88US=> MWPTRW5ITVJ?
MZ7-mel NFizcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXT[Jp2UUN3ME2wMlE4PjR7IN88US=> Ml\HV2FPT0WU
NCI-H650 NXz1TmVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfubJNqUUN3ME2wMlE4Pjh{IN88US=> Mn22V2FPT0WU
KOSC-2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojzTWM2OD1yLkG3O|M1KM7:TR?= NETi[lhUSU6JRWK=
SCC-4 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrKTWM2OD1yLkG3O|c4KM7:TR?= M4PkbnNCVkeHUh?=
MDA-MB-157 NGe3R5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrrR5NKSzVyPUCuNVgxQDJizszN NEXoeG9USU6JRWK=
KYSE-520 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTuVmZPUUN3ME2wMlE5OiEQvF2= MYLTRW5ITVJ?
LK-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnLTWM2OD1yLkG4N|A{KM7:TR?= NGnwNFNUSU6JRWK=
KNS-81-FD MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwMUizPVQh|ryP MVHTRW5ITVJ?
IGROV-1 MlXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwMUi0OFMh|ryP M{K5T3NCVkeHUh?=
DEL NWTVeZhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TrUGlEPTB;MD6xPFQ2KM7:TR?= MlT2V2FPT0WU
NCI-H1395 NXv5ZYF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwMUi2PFIh|ryP MoXXV2FPT0WU
JEG-3 Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrIPGRVUUN3ME2wMlE5PzB3IN88US=> NX2yb5VZW0GQR1XS
BCPAP NIfteo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTTTWM2OD1yLkG4PFczKM7:TR?= NEGwcWxUSU6JRWK=
CAL-27 M3jPXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwMUmwNlIh|ryP M1Xkd3NCVkeHUh?=
RD Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;hTWM2OD1yLkG5NVE{KM7:TR?= M2jPU3NCVkeHUh?=
RVH-421 NYrzV5AyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVX0SWNiUUN3ME2wMlE6OTF4IN88US=> MVnTRW5ITVJ?
Capan-2 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLBSldKSzVyPUCuNVkzPTZizszN MWrTRW5ITVJ?
COLO-680N NFPkOlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXixVHFoUUN3ME2wMlE6OzZ2IN88US=> M2X3[3NCVkeHUh?=
NCI-H1650 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwMkCwOVch|ryP NH7EXFlUSU6JRWK=
SBC-5 NV;OSZI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3VTIdZUUN3ME2wMlIxOTF6IN88US=> M3XzXHNCVkeHUh?=
U031 NFqxepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jYbmlEPTB;MD6yNFU1PyEQvF2= MnHxV2FPT0WU
S-117 MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Hme2lEPTB;MD6yNFU3PCEQvF2= NH\yVFJUSU6JRWK=
DoTc2-4510 M2jUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1n0UmlEPTB;MD6yNFc3QSEQvF2= MVfTRW5ITVJ?
AM-38 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXJUVJKSzVyPUCuNlA5PDhizszN Mke0V2FPT0WU
A172 MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm0TWM2OD1yLkKxNFIzKM7:TR?= Mkm3V2FPT0WU
HPAF-II MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7pTWM2OD1yLkKxNlY1KM7:TR?= MnvPV2FPT0WU
769-P M1rXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjhPZJKSzVyPUCuNlEzQCEQvF2= MXnTRW5ITVJ?
MFE-280 Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMkGyPVgh|ryP MWfTRW5ITVJ?
TE-9 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP2TWM2OD1yLkKxO|g3KM7:TR?= M4fTWXNCVkeHUh?=
C2BBe1 NF;4OllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnFTWM2OD1yLkKyNVkh|ryP MlPSV2FPT0WU
EoL-1-cell MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\YTWM2OD1yLkKyNlA{KM7:TR?= MWTTRW5ITVJ?
G-361 NYLqSo05T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnPcI1LUUN3ME2wMlIzPjh{IN88US=> MlKyV2FPT0WU
KYSE-270 M171[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV6zOVJJUUN3ME2wMlI{ODh2IN88US=> MXTTRW5ITVJ?
TK10 NHq3UmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HMcmlEPTB;MD6yN|EyPyEQvF2= M4rDTnNCVkeHUh?=
ML-2 NF34SWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwMkOxNVkh|ryP NU\hU2R7W0GQR1XS
MHH-ES-1 Mk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrDcoRKSzVyPUCuNlM3QDFizszN M2PsPHNCVkeHUh?=
BHY MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwMkO2PVEh|ryP M{XWfHNCVkeHUh?=
LS-513 MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;ON|VKSzVyPUCuNlM6PjFizszN NX3qb2NGW0GQR1XS
COLO-678 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nJdGlEPTB;MD6yOFA1PCEQvF2= NHjSVndUSU6JRWK=
NCI-H747 MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVf6TGY4UUN3ME2wMlI1OTZ7IN88US=> NFPCd4RUSU6JRWK=
K5 NGrFbppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4GzeWlEPTB;MD6yOFM5KM7:TR?= NWK1cIdQW0GQR1XS
OS-RC-2 M4jpVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDoR4RKSzVyPUCuNlQ2ODlizszN MWrTRW5ITVJ?
KINGS-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPSTWM2OD1yLkK0OVI6KM7:TR?= NVnnfoFnW0GQR1XS
SCC-25 NW\GcnNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV74N2tnUUN3ME2wMlI1PTZ|IN88US=> M4jrOHNCVkeHUh?=
CAPAN-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGCyT4pKSzVyPUCuNlQ4QDNizszN NVLMSoFzW0GQR1XS
ESS-1 M3jqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLqV5NKSzVyPUCuNlQ5ODVizszN MWTTRW5ITVJ?
TE-6 NILkVHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMkW3OUDPxE1? NVfGS4xQW0GQR1XS
LB2518-MEL NUHJUXBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XNVmlEPTB;MD6yOVc4PyEQvF2= MXLTRW5ITVJ?
COLO-800 NIHkPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\lTWM2OD1yLkK1PFEzKM7:TR?= NFvCZnRUSU6JRWK=
LU-134-A MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDQTVlZUUN3ME2wMlI3OTN4IN88US=> MkPnV2FPT0WU
NCI-H1155 MknqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PDNWlEPTB;MD6yOlE3OiEQvF2= MXzTRW5ITVJ?
MFM-223 MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfyeoZKSzVyPUCuNlY{PjNizszN MnS5V2FPT0WU
HTC-C3 NF\pcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\wWmlEPTB;MD6yOlUxPiEQvF2= MmrqV2FPT0WU
HCT-116 M{fQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\4d2lEPTB;MD6yOlU6QSEQvF2= NFL2OJVUSU6JRWK=
Ca-Ski M1TKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMk[2O|gh|ryP NYnmUFlVW0GQR1XS
SBC-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33tWmlEPTB;MD6yOlc1OiEQvF2= MoqxV2FPT0WU
NB69 NFzYfVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmntTWM2OD1yLkK3NFg4KM7:TR?= NV\EV5pvW0GQR1XS
J82 M2X4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfOTWM2OD1yLkK3NlY2KM7:TR?= NVXyUmZ4W0GQR1XS
U-118-MG MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfhTWtKSzVyPUCuNlc2PzlizszN MXvTRW5ITVJ?
NCI-H1355 Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwMkiwO|Qh|ryP NXnFO|RwW0GQR1XS
NCI-H1048 M1;Sc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwMki5OVYh|ryP NIfaWXdUSU6JRWK=
SW954 NIPMVFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLLSYdMUUN3ME2wMlI6OjJ5IN88US=> M3frXXNCVkeHUh?=
NMC-G1 M{DuUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjRSYtKSzVyPUCuNlkzPzdizszN MXvTRW5ITVJ?
SW1710 NX:xNWZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ToT2lEPTB;MD6yPVQ6PCEQvF2= MVrTRW5ITVJ?
KY821 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnmNZplUUN3ME2wMlI6QDd{IN88US=> M1vhPHNCVkeHUh?=
HCC38 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwM{CwO|gh|ryP NX\PdoZOW0GQR1XS
NCI-SNU-5 NYHDV|lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULU[Xp3UUN3ME2wMlMxPTRizszN M2SwR3NCVkeHUh?=
ES8 M3nYXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVj3[3BvUUN3ME2wMlMxPzh2IN88US=> NIntfFNUSU6JRWK=
COLO-792 NXj1OW9OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwM{GyOVEh|ryP NYHQRpZJW0GQR1XS
BFTC-905 NWS2SJRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj4TWM2OD1yLkOxOVIyKM7:TR?= NVz3Wmt{W0GQR1XS
ChaGo-K-1 M4nM[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwM{G3NVUh|ryP MmjjV2FPT0WU
Daoy MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknVTWM2OD1yLkOxO|I{KM7:TR?= NXzmXopVW0GQR1XS
SJSA-1 Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX76T4Y5UUN3ME2wMlMyQDR5IN88US=> M{exOXNCVkeHUh?=
KNS-62 M4LTbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnCRYpiUUN3ME2wMlMzODh6IN88US=> NF;oe2ZUSU6JRWK=
CAKI-1 NFXwZ4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwM{KxNVEh|ryP MXPTRW5ITVJ?
UACC-62 M2rPbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwM{KyNlch|ryP MnXOV2FPT0WU
HuCCT1 MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O0VGlEPTB;MD6zNlI5OyEQvF2= NXrpcoplW0GQR1XS
CTB-1 M2fsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTyfJVbUUN3ME2wMlMzPzV|IN88US=> NVLPU3ZsW0GQR1XS
NTERA-S-cl-D1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7aeYQxUUN3ME2wMlMzQDN4IN88US=> MWDTRW5ITVJ?
T-24 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fISmlEPTB;MD6zN|E2QSEQvF2= NHLwU49USU6JRWK=
KYSE-70 M2LLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTKRnc{UUN3ME2wMlM{Ojh|IN88US=> NYPJSG06W0GQR1XS
SW626 NUTFbXJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj3TWM2OD1yLkOzOVMzKM7:TR?= NF3wNVlUSU6JRWK=
LB996-RCC NUTHUIhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2mwUWlEPTB;MD6zN|YyQSEQvF2= NVHGd2RnW0GQR1XS
DMS-273 MoDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTMTWM2OD1yLkOzPVE3KM7:TR?= NHTLZWxUSU6JRWK=
SW1783 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nRSWlEPTB;MD6zN|k6PyEQvF2= M2KydHNCVkeHUh?=
KU812 MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHxUnNWUUN3ME2wMlM1ODN6IN88US=> MYfTRW5ITVJ?
HSC-2 NI\LNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;jTWM2OD1yLkO0NFU{KM7:TR?= MUfTRW5ITVJ?
A3-KAW NWDObXNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwM{SxOlIh|ryP Mn\hV2FPT0WU
COLO-684 M33iPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPhRZFKSzVyPUCuN|Q2ODFizszN Mn;hV2FPT0WU
NCI-H2405 Ml3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwM{S2N|Eh|ryP NUi0e4loW0GQR1XS
NCI-H2228 NE[zUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwM{WzOVch|ryP MV\TRW5ITVJ?
NB13 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XvWmlEPTB;MD6zOlgzQSEQvF2= M3zoVnNCVkeHUh?=
no-11 M3vCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwM{[5OUDPxE1? MV\TRW5ITVJ?
DK-MG NXPaTplwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXMO2tVUUN3ME2wMlM4OTh6IN88US=> NU\1W21UW0GQR1XS
NBsusSR MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnXfGZ5UUN3ME2wMlM4Ojh3IN88US=> M1nKd3NCVkeHUh?=
KP-N-YS NH3IZ2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPwbmhKSzVyPUCuN|c1PjNizszN Ml\CV2FPT0WU
CFPAC-1 MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfX[W12UUN3ME2wMlM4PTF6IN88US=> NHqydWhUSU6JRWK=
KARPAS-45 M2fzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUj1boJ1UUN3ME2wMlM4QDZ{IN88US=> NWLqflJjW0GQR1XS
NCI-H1793 NI\Keo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnPXXVKSzVyPUCuN|g2OSEQvF2= MknwV2FPT0WU
HCE-T MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjvcnBnUUN3ME2wMlM5PjB|IN88US=> NYe3THlTW0GQR1XS
NCI-H520 NXj6W|Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LsOGlEPTB;MD6zPFcxOyEQvF2= MYfTRW5ITVJ?
HCC2157 MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwM{i3PFEh|ryP NWLlPXRUW0GQR1XS
EW-18 NELS[3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2raeWlEPTB;MD6zPFk1OSEQvF2= NGfEWY1USU6JRWK=
RO82-W-1 NHz2fmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;aTWM2OD1yLkO5Olk6KM7:TR?= NX:y[4Y2W0GQR1XS
HuP-T3 Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XYNGlEPTB;MD60NFE1OyEQvF2= NWCxOWxOW0GQR1XS
PANC-10-05 NULiV2VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrkOmMxUUN3ME2wMlQyOTdizszN MoDnV2FPT0WU
NCI-H1703 NGjKS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUW1XVU2UUN3ME2wMlQyPDR4IN88US=> Mn;uV2FPT0WU
TE-10 M1jadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfzTWM2OD1yLkSxOFQ4KM7:TR?= NETKWVBUSU6JRWK=
HOS NVrUOI1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoKyTWM2OD1yLkSxOlgzKM7:TR?= NXrjbW5[W0GQR1XS
LN-405 M1e0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13rTWlEPTB;MD60NVY5PyEQvF2= NYTCW|hDW0GQR1XS
A427 NFXZSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:2VWlEPTB;MD60NVk5OSEQvF2= MluyV2FPT0WU
CAL-12T NUjDbpo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\tTWM2OD1yLkSyO|gh|ryP NWLsSHhRW0GQR1XS
SW756 M1j4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLDSZpKSzVyPUCuOFQyQDNizszN NXu0UFVVW0GQR1XS
YAPC M3myOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwNEWwPEDPxE1? MnPiV2FPT0WU
GOTO Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\3UFlKSzVyPUCuOFUyPiEQvF2= M3Tpe3NCVkeHUh?=
C3A NVrWc|F3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXIWY5KSzVyPUCuOFU1OzdizszN M{jxU3NCVkeHUh?=
UM-UC-3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fZbmlEPTB;MD60OVQ4KM7:TR?= M2Dl[HNCVkeHUh?=
NCI-H1573 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlizTWM2OD1yLkS1OVY6KM7:TR?= M3T2PHNCVkeHUh?=
LS-411N MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\jZZZbUUN3ME2wMlQ3PTJ5IN88US=> MlzWV2FPT0WU
COR-L23 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTvTWM2OD1yLkS2O|Y1KM7:TR?= M4LRS3NCVkeHUh?=
HCE-4 NHiz[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknVTWM2OD1yLkS3OFQ3KM7:TR?= M1riOnNCVkeHUh?=
NCI-H2291 M3vGcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwNEe4PVYh|ryP NGTlNplUSU6JRWK=
A101D NHHkN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;EZoVKSzVyPUCuOFgxPTNizszN MUDTRW5ITVJ?
HT-3 NHv2b4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwNEiyNVch|ryP M3z5TnNCVkeHUh?=
HOP-62 NFK2UZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEf2epZKSzVyPUCuOFk5PjVizszN M1f2PHNCVkeHUh?=
PC-3 NWe0bmNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnOTWM2OD1yLkWxOVA4KM7:TR?= M17senNCVkeHUh?=
CTV-1 NIW0[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjjTWM2OD1yLkWyOlY6KM7:TR?= NHrKN2dUSU6JRWK=
PANC-08-13 NIHFdG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwNUOxO|ch|ryP NYfyRWs4W0GQR1XS
CAL-120 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlWyTWM2OD1yLkWzN|k6KM7:TR?= NHX0eJZUSU6JRWK=
UMC-11 NV3KPXd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEf5TnNKSzVyPUCuOVUzOzRizszN MXfTRW5ITVJ?
MSTO-211H NF\ZRVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfaNGZJUUN3ME2wMlU2PzZ{IN88US=> NInMSHZUSU6JRWK=
NCI-H2126 MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwNU[4NVUh|ryP Mk\5V2FPT0WU
SNU-C2B NHfQenVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwNUe5O|ch|ryP Mmf6V2FPT0WU
DBTRG-05MG Mlv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{T2U2lEPTB;MD61PFA2OyEQvF2= NVvLWI5uW0GQR1XS
MKN1 NGTRV5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTYTWM2OD1yLkW4O|g{KM7:TR?= MUXTRW5ITVJ?
ES3 MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHUWJhKSzVyPUCuOVkyOjRizszN M{TBTHNCVkeHUh?=
OVCAR-3 NGrSfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFK0OJBKSzVyPUCuOVk{PDFizszN NWfYW3EzW0GQR1XS
ACHN NVmwPY86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnj2TWM2OD1yLk[wOVY6KM7:TR?= NHXoT5VUSU6JRWK=
SW872 NFzQZ3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfi[Zp[UUN3ME2wMlYxPzZ|IN88US=> NV7KWm51W0GQR1XS
CP66-MEL NETiNpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwNkC5Olkh|ryP MojyV2FPT0WU
NCI-H661 MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmWyTWM2OD1yLk[xNVA1KM7:TR?= NWrlenpUW0GQR1XS
UACC-893 M1vUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjnWW9KSzVyPUCuOlM3QDFizszN NEDhVphUSU6JRWK=
JVM-3 NYXNWJVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;0TWM2OD1yLk[zPFA1KM7:TR?= MX\TRW5ITVJ?
SF268 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\xSXdKSzVyPUCuOlQ{PDlizszN M3HQeHNCVkeHUh?=
OCI-AML2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXjTWM2OD1yLk[1N|k4KM7:TR?= MYjTRW5ITVJ?
RPMI-8226 M2ew[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnN[XhKSzVyPUCuOlY{OjNizszN NVvoTWhuW0GQR1XS
MKN28 NH;MSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LIT2lEPTB;MD62OlYzPCEQvF2= NGDHcmFUSU6JRWK=
MDA-MB-453 M{jnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfhOJBkUUN3ME2wMlY4OThizszN MVvTRW5ITVJ?
BV-173 M3jtV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXP4PZVpUUN3ME2wMlY5Pjd7IN88US=> NWPYWHl7W0GQR1XS
NCI-H358 M13wXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDYVFdKSzVyPUCuOlg4OjZizszN MUTTRW5ITVJ?
NCI-H1651 M3P3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zVc2lEPTB;MD63JO69VQ>? NHfhXGxUSU6JRWK=
MDA-MB-415 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnJc2VKSzVyPUCuO|A5OjlizszN MUDTRW5ITVJ?
8305C MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TIS2lEPTB;MD63NlQ6QCEQvF2= MmTPV2FPT0WU
EFM-19 M4DWeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jY[mlEPTB;MD63N|Y4OSEQvF2= Mlz3V2FPT0WU
RERF-LC-MS NXfrcFNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7MUZdKSzVyPUCuO|Q3OTNizszN NFrrfnRUSU6JRWK=
A388 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTKTWM2OD1yLke2OFY4KM7:TR?= M3T6UnNCVkeHUh?=
GI-ME-N MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfC[oNKUUN3ME2wMlc4OjN3IN88US=> Mo\pV2FPT0WU
IGR-1 NWe0V|NRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;mRmlEPTB;MD63PVA1OyEQvF2= MorwV2FPT0WU
LNCaP-Clone-FGC M2nrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mme3TWM2OD1yLkiwNFA1KM7:TR?= Mo\5V2FPT0WU
SK-MEL-3 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoK3TWM2OD1yLkixOVA5KM7:TR?= Mn[3V2FPT0WU
UACC-257 M1fPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHewblhKSzVyPUCuPFIzOzFizszN NWP4PWFyW0GQR1XS
OE33 MoDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHSxbWJKSzVyPUCuPFUyODFizszN MVfTRW5ITVJ?
QIMR-WIL NIT4VnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NISwTWxKSzVyPUCuPFUyPDFizszN NIjaem5USU6JRWK=
NCI-H2009 NWDTeIo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\ITWM2OD1yLki1N|EyKM7:TR?= MX;TRW5ITVJ?
NCI-H522 MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwOEe3PFMh|ryP NI[yZ5BUSU6JRWK=
Saos-2 MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HXdGlEPTB;MD64O|g4OSEQvF2= M2nFfHNCVkeHUh?=
NB17 NHTJPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\3d3NKSzVyPUCuPFgxOjVizszN MXXTRW5ITVJ?
D-392MG M{LEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3u5c2lEPTB;MD64PVM2PiEQvF2= MXrTRW5ITVJ?
SHP-77 MmnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwOUC0PFUh|ryP MmjGV2FPT0WU
SK-MEL-30 M1HjWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPvfIdyUUN3ME2wMlkyOTh3IN88US=> MmTWV2FPT0WU
GCIY NXy3dVJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\uN5NKSzVyPUCuPVE5PDNizszN MX;TRW5ITVJ?
HCC70 NVnIc2xmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvmcHVnUUN3ME2wMlkzODV7IN88US=> NF\jZVBUSU6JRWK=
LU-65 MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4L1V2lEPTB;MD65NlU6OSEQvF2= M13sb3NCVkeHUh?=
NCI-H1563 MnHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnYTWM2OD1yLkm0PFY2KM7:TR?= Ml2yV2FPT0WU
KURAMOCHI M3fkXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwOUWxPVIh|ryP NELibJdUSU6JRWK=
PA-1 NUDsVHJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVL2XHJJUUN3ME2wMlk2PDJ2IN88US=> NIW2fYVUSU6JRWK=
NOS-1 NGfUTJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwOUe0PFkh|ryP MXTTRW5ITVJ?
NCI-H69 NV:x[2hrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3frZWlEPTB;MD65O|Y{PCEQvF2= NVfIXo9kW0GQR1XS
KYSE-450 MnjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\sZ2lEPTB;MD65PFYzPiEQvF2= NV;pTYVzW0GQR1XS
8505C NIWwWmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULwVJg3UUN3ME2wMlk6QTh{IN88US=> MVjTRW5ITVJ?
TGBC24TKB NEDFOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTFwMECwPFQh|ryP MomxV2FPT0WU
PFSK-1 NH32b2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvnenhKSzVyPUGuNFE1OjhizszN M1XmNXNCVkeHUh?=
EKVX M2\XSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFu0UXJKSzVyPUGuNFMyOjFizszN M173S3NCVkeHUh?=
RCM-1 NXO0VY5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTFwMEW1NFch|ryP Mm[5V2FPT0WU
SW900 M4DITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPtTWM2OD1zLkC3PFMh|ryP M1vLfnNCVkeHUh?=
D-542MG MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTFwMEe4OVUh|ryP MVnTRW5ITVJ?
SK-PN-DW MoC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\veWlEPTB;MT6xNFA2PiEQvF2= MW\TRW5ITVJ?
NCI-H727 M1XMW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDo[mVnUUN3ME2xMlExOTV2IN88US=> M{Xn[HNCVkeHUh?=
SW837 NVL6WJcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPKcYNKSzVyPUGuNVA6PTRizszN NYTEboJkW0GQR1XS
BT-20 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PETmlEPTB;MT6xNVIxPCEQvF2= MmW3V2FPT0WU
RH-18 NXXq[IRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfFTWM2OD1zLkGzNVA{KM7:TR?= NFq5[4pUSU6JRWK=
TE-12 NYW3XllET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\hdWlEPTB;MT6xN|M{OyEQvF2= NVvoWpQyW0GQR1XS
NB10 NYjmfG9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PTXWlEPTB;MT6xN|M1PCEQvF2= NUX3b|dZW0GQR1XS
AU565 NXjvR5E6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HEV2lEPTB;MT6xOVk4OyEQvF2= MV7TRW5ITVJ?
OAW-42 NVjKfmlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vDVmlEPTB;MT6xPFMxPiEQvF2= M1[3fnNCVkeHUh?=
DJM-1 NWfXV4V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7XTWM2OD1zLkG5PFgyKM7:TR?= NXrMXWlNW0GQR1XS
HH Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DLb2lEPTB;MT6yN|g{OSEQvF2= M3rIbHNCVkeHUh?=
LAMA-84 NXjDN2FsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFwMkezPVQh|ryP MkTTV2FPT0WU
KNS-42 NEGzeFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml35TWM2OD1zLkOwNlk3KM7:TR?= M1vNOnNCVkeHUh?=
NCI-H2052 M1\L[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjJTlFDUUN3ME2xMlMxPTB5IN88US=> MmPZV2FPT0WU
MLMA Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzVZ4hKSzVyPUGuN|I1ODdizszN NHnCSolUSU6JRWK=
NB12 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzBTWM2OD1zLkO1OlM3KM7:TR?= NWHBTJFSW0GQR1XS
NCI-H1838 M364emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;4WGlEPTB;MT6zOlMxPiEQvF2= MXfTRW5ITVJ?
NCI-H526 NFzCT3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2f3cmlEPTB;MT6zO|g2OyEQvF2= NHjZTGVUSU6JRWK=
LS-123 NWD4U4ppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIG3eJpKSzVyPUGuN|kxQTRizszN NWS2eWxVW0GQR1XS
HDLM-2 M36zVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoK2TWM2OD1zLkO5NlcyKM7:TR?= MV;TRW5ITVJ?
MC-IXC MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTFwNEKzO|Eh|ryP MnPIV2FPT0WU
HCT-15 M3Pw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTp[ItVUUN3ME2xMlQ{ODZ6IN88US=> NXiybmxCW0GQR1XS
NCI-H596 M1e5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3UVIZKSzVyPUGuOFUxPjFizszN M1vzbHNCVkeHUh?=
ZR-75-30 MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vteWlEPTB;MT60O|A5OiEQvF2= MYfTRW5ITVJ?
A704 MoTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LjS2lEPTB;MT62OlU3OyEQvF2= MXTTRW5ITVJ?
OVCAR-4 M{\sZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIiyR3pKSzVyPUGuOlk3ODdizszN M4jUXnNCVkeHUh?=
SW1417 M3nGSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTpTWM2OD1zLkeyPFQ6KM7:TR?= NY[wU2NYW0GQR1XS
CAS-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvXbXlKSzVyPUGuO|M6OzZizszN NYG3SGZ6W0GQR1XS
IST-SL1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLZdGhKSzVyPUGuO|k4PTlizszN M4LsVXNCVkeHUh?=
A253 NYXu[|NCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTYeHB4UUN3ME2xMlgzOjN7IN88US=> MlT4V2FPT0WU
EW-16 NHvISY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmiwTWM2OD1zLkiyPFc2KM7:TR?= M2LvOXNCVkeHUh?=
SK-NEP-1 NGfFdGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjMWJVLUUN3ME2xMlg3QTh6IN88US=> M33VN3NCVkeHUh?=
NCI-H226 M{\XfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXnOYkyUUN3ME2xMlg6OzV7IN88US=> M{D3VHNCVkeHUh?=
HOP-92 NXXzfWtGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nIUGlEPTB;MT65OlA6QSEQvF2= MXLTRW5ITVJ?
NCI-H441 Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf1TWM2OD1{LkCyN|M4KM7:TR?= Mn;QV2FPT0WU
LU-139 MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTJwMEOxNVQh|ryP NVjYOJJCW0GQR1XS
SJRH30 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFf2WXVKSzVyPUKuNFQzPTNizszN MofCV2FPT0WU
MG-63 M{TnNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnH3TWM2OD1{LkG0NVEyKM7:TR?= Mn3lV2FPT0WU
NH-12 NI\xNXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJwMUWwNFYh|ryP MUTTRW5ITVJ?
NB7 NGr3bJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MluyTWM2OD1{LkG5Olc{KM7:TR?= MXvTRW5ITVJ?
LB771-HNC M4rp[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDQTWM2OD1{LkKwOVk2KM7:TR?= M4Pzc3NCVkeHUh?=
HCC1569 MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTJwMkS1PFMh|ryP M1n0c3NCVkeHUh?=
D-283MED MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HaZmlEPTB;Mj6yOFc5OiEQvF2= NGTj[oRUSU6JRWK=
J-RT3-T3-5 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHvTWM2OD1{LkK1N|UyKM7:TR?= M4XYdXNCVkeHUh?=
ATN-1 NXnxPGlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PTRWlEPTB;Mj6zN|A5OiEQvF2= NWXuVHV6W0GQR1XS
HCC1954 M3vMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4i3fGlEPTB;Mj6zOFQxQCEQvF2= M4fBPHNCVkeHUh?=
SCC-15 M1Pwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHteVRKSzVyPUKuN|k{OTJizszN MXTTRW5ITVJ?
COLO-668 MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHhRZFKSzVyPUKuOFMzKM7:TR?= MYLTRW5ITVJ?
LB373-MEL-D M4facmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIixN|dKSzVyPUKuOVQ3PzdizszN M1LVUnNCVkeHUh?=
no-10 MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\ETWM2OD1{LkW0PVQ4KM7:TR?= MlLGV2FPT0WU
HT-1197 M4[0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofsTWM2OD1{Lk[zNVg5KM7:TR?= MmDyV2FPT0WU
DU-145 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWqz[XhuUUN3ME2yMlc6OTZ{IN88US=> MULTRW5ITVJ?
SK-N-AS NYTGXYlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nrRWlEPTB;Mj64OFY6OiEQvF2= MmjhV2FPT0WU
MOLT-4 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\iTWM2OD1{Lki1N|IzKM7:TR?= MkTzV2FPT0WU
EW-22 NWfGXYpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3WTWM2OD1{LkmyPFQyKM7:TR?= NGrhWIpUSU6JRWK=
DB NX\JOWJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnPTWM2OD1{Lkm3O|U6KM7:TR?= NHvpXpdUSU6JRWK=
HL-60 MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj4W5NKSzVyPUOuNFQ{PzZizszN NG\nd|lUSU6JRWK=
SK-N-DZ NH:xNlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHrS|BLUUN3ME2zMlA2ODd3IN88US=> NF;afW9USU6JRWK=
NY MnzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\oT2lEPTB;Mz6wPFU1OiEQvF2= M{joXXNCVkeHUh?=
T47D NE\BTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlf5TWM2OD1|LkGwOVU5KM7:TR?= M2O4NHNCVkeHUh?=
NCI-H2029 MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHwS3VKSzVyPUOuNlI1PzdizszN MVjTRW5ITVJ?
KARPAS-299 NHnzPG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPIO4hpUUN3ME2zMlI3ODJ5IN88US=> Ml;rV2FPT0WU
KM-H2 M17R[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTNwM{C2PEDPxE1? M3G3UXNCVkeHUh?=
CHP-134 M2rNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjhPGVtUUN3ME2zMlQ4OzlizszN MoDUV2FPT0WU
22RV1 MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHKOJNKSzVyPUOuOFkyPjhizszN NXyyW|hRW0GQR1XS
NB5 NXrxR|l5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILDPFBKSzVyPUOuOVA3QDlizszN NVn4c|JRW0GQR1XS
CW-2 M13OTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\j[WFCUUN3ME2zMlU2OzF2IN88US=> M4TCOnNCVkeHUh?=
EFO-21 NYDj[nFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[wcmlEPTB;Mz61Olk1KM7:TR?= MmqzV2FPT0WU
HuH-7 NETJWYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPTTWM2OD1|LkW4OFE1KM7:TR?= MX7TRW5ITVJ?
ALL-PO NXHi[VRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jLTmlEPTB;Mz62NlM{PSEQvF2= M1nnSnNCVkeHUh?=
EM-2 NVPl[3FKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nyRWlEPTB;Mz62PVAyOSEQvF2= NVPZfGRHW0GQR1XS
KLE MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDRW4dKSzVyPUOuO|MxOjlizszN MULTRW5ITVJ?
NEC8 M37JO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vZWGlEPTB;Mz65NVgxQCEQvF2= M{nIXHNCVkeHUh?=
KP-N-YN M2nad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7HTWM2OD1|LkmzOFc3KM7:TR?= NEXVeGFUSU6JRWK=
SK-MEL-1 NGLDTolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:xRoJKSzVyPUSuNFM2OThizszN NULnNVVSW0GQR1XS
CAL-54 MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTRwMEW5NUDPxE1? MXnTRW5ITVJ?
MS-1 MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLMTWM2OD12LkG2NVU2KM7:TR?= NXrzbJVVW0GQR1XS
NCI-H209 NVzCTFVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\QeGlEPTB;ND6yPVk6QSEQvF2= MnrGV2FPT0WU
NOMO-1 NV3QbXRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTRwM{KxN|Eh|ryP MomzV2FPT0WU
RPMI-2650 M{TpOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTRwM{[zNlch|ryP NX[0e5N3W0GQR1XS
NCI-H810 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fUdGlEPTB;ND6zPVc{PiEQvF2= MlHhV2FPT0WU
Ca9-22 MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jNSWlEPTB;ND60OVY6OSEQvF2= MYjTRW5ITVJ?
ES4 M2rqT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTHUJlzUUN3ME20MlQ4ODl3IN88US=> NGjqeVZUSU6JRWK=
ES6 NIi1OGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTRwNEm2OVch|ryP MlTPV2FPT0WU
DMS-114 NXm4TnRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPDTW5KSzVyPUSuOVQ3QTFizszN NI\pVHNUSU6JRWK=
ONS-76 NXyxSVhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWf0XXRoUUN3ME20MlU4QTVizszN MkDwV2FPT0WU
K-562 NIfnU3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIn4bFBKSzVyPUSuO|M5OTRizszN MY\TRW5ITVJ?
MHH-NB-11 MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTRwN{W0OlEh|ryP NUXjPGxzW0GQR1XS
Calu-3 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjpXWZKSzVyPUSuO|g2PDhizszN M2qyXHNCVkeHUh?=
HT55 MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\PTWM2OD12Lki0OVQ2KM7:TR?= MYfTRW5ITVJ?
SK-N-FI Mm\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnizTWM2OD12Lki1NFA6KM7:TR?= MmrQV2FPT0WU
ES1 NVzJT5Z1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj1TWM2OD12Lki2NFU4KM7:TR?= NV71OG9bW0GQR1XS
SF126 MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjYbVRkUUN3ME20Mlk{OTh2IN88US=> M2LP[3NCVkeHUh?=
ES5 M2XGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTVwMUK0Nlch|ryP MUXTRW5ITVJ?
LoVo MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLj[3BKSzVyPUWuNVU5PzFizszN NXjsO4FiW0GQR1XS
SNU-387 Mo\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnmzTWM2OD13LkOyN|M6KM7:TR?= NUjMTFM6W0GQR1XS
C8166 MnPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTVwM{[zN|kh|ryP M{GzZ3NCVkeHUh?=
LS-1034 NHfRT|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LzOGlEPTB;NT60NlMxPyEQvF2= NGTrVHJUSU6JRWK=
GR-ST M1P4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTVwNUKyNFEh|ryP MkjoV2FPT0WU
NCI-H1092 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TheWlEPTB;NT63Nlg1OyEQvF2= NH;abZhUSU6JRWK=
647-V MlLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jre2lEPTB;NT63OFcxPiEQvF2= NEPv[YxUSU6JRWK=
EW-13 NVnSNJB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDwSIZOUUN3ME21Mlc3PjJ5IN88US=> MlrQV2FPT0WU
KGN NF3ifm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{O1UGlEPTB;Nj6wPVkzOSEQvF2= M3zaR3NCVkeHUh?=
D-423MG M4fBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHxeY9KSzVyPU[uOFAzQDRizszN NYfXT5MxW0GQR1XS
ECC10 NV3xWXV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HJV2lEPTB;Nz6xNFExOSEQvF2= MmCwV2FPT0WU
TE-5 NInDVGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Hn[2lEPTB;Nz60NVI6QCEQvF2= M1v5PXNCVkeHUh?=
P12-ICHIKAWA M4jiOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moj6TWM2OD15LkS1OVI{KM7:TR?= M{\sdXNCVkeHUh?=
NCI-H82 NF\Xc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGW2c4RKSzVyPUeuOFU4ODFizszN NEn6VpVUSU6JRWK=
NCI-H1993 NYe3WY9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPZN|NKSzVyPUeuPFMxPjNizszN NGD3[pVUSU6JRWK=
RH-1 NFjN[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXGUJZKSzVyPUeuPFUzPDRizszN MUjTRW5ITVJ?
SW948 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTdwOU[wOFkh|ryP NW[1OJdzW0GQR1XS
CAL-33 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP5NmJKSzVyPUeuPVk6OzhizszN NGOyO3dUSU6JRWK=
U-266 NUKxbVJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[zTWM2OD16LkG1O|c4KM7:TR?= NILhb2hUSU6JRWK=
CAL-72 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFO2c5pKSzVyPUiuNlA{OiEQvF2= MmXPV2FPT0WU
SNU-423 M{DLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mny0TWM2OD17LkO2OlY3KM7:TR?= MnfXV2FPT0WU
KG-1 NXfmPWlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPoTWM2OD17LkW4OFU3KM7:TR?= NETrcI1USU6JRWK=
HCC1395 NHPQT3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PLb2lEPTB;OT65NlM2OiEQvF2= MWjTRW5ITVJ?
BE-13 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\HWIZKSzVyPUGwMlg5QTJizszN MULTRW5ITVJ?
MKN7 NVfoVIxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFyLkm3OlUh|ryP MmDxV2FPT0WU
697 MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDSS|hRUUN3ME2xNU4yPDd{IN88US=> Moe0V2FPT0WU
LU-135 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDC[lNKSzVyPUGxMlI{ODdizszN M2fNWXNCVkeHUh?=
ES7 MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjUVpAzUUN3ME2xNU4{OzF|IN88US=> NFq2TZlUSU6JRWK=
SK-HEP-1 NHH6dXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTFzLke2OFYh|ryP NUewNlI1W0GQR1XS
BEN MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTFzLki1NUDPxE1? Mn7wV2FPT0WU
NCI-H1770 MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[5cmlEPTB;MUKuNVI3KM7:TR?= NHfHN4VUSU6JRWK=
SW13 NVj4U5NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTF{LkG1OFEh|ryP M{PSOnNCVkeHUh?=
MZ1-PC NVjYVJg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTF{LkW0OVIh|ryP MWPTRW5ITVJ?
Mo-T M2Tvcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1i1WWlEPTB;MUKuO|QzOSEQvF2= NHTl[VBUSU6JRWK=
HLE Mn7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF{LkiyNVUh|ryP MoXNV2FPT0WU
RCC10RGB NVq3bYN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\jTWM2OD1zMz62O|Eh|ryP NVXlVpdIW0GQR1XS
COLO-320-HSR NFjJZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfNTWM2OD1zMz63N|gyKM7:TR?= NXLYNVd[W0GQR1XS
BHT-101 M4fLOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUO5eVd[UUN3ME2xN{45OzR3IN88US=> NVPneHRJW0GQR1XS
OCUB-M NH7teIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWH2ZZVoUUN3ME2xOE4yPjB{IN88US=> MVnTRW5ITVJ?
MEG-01 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTF2LkO3NFgh|ryP MUPTRW5ITVJ?
RS4-11 M4frNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPRWFhKSzVyPUG0Mlc1OiEQvF2= MmrhV2FPT0WU
MN-60 NHvkTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfoeYJ6UUN3ME2xOE44QDl2IN88US=> MljCV2FPT0WU
NCI-H1304 NFL5bY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L2dWlEPTB;MUWuNFQzPSEQvF2= NVzoTXV5W0GQR1XS
Ramos-2G6-4C10 MkPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLpTWM2OD1zNT6wOVgyKM7:TR?= M37hdnNCVkeHUh?=
NCI-H2342 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfCU4UyUUN3ME2xOU4zODR2IN88US=> MUTTRW5ITVJ?
LAN-6 NF[wTpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfndVJKSzVyPUG1MlQ1OTRizszN M{jkdXNCVkeHUh?=
JVM-2 Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvpbHdKSzVyPUG1MlU4PDhizszN NWPqb|FMW0GQR1XS
P30-OHK M{L2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTF4LkC2NVQh|ryP MXXTRW5ITVJ?
C-33-A MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnhNnNDUUN3ME2xOk43OjF2IN88US=> NHnSWJVUSU6JRWK=
RPMI-8866 NXXZbYRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPzOGlQUUN3ME2xOk45PDl4IN88US=> M3nlUXNCVkeHUh?=
NCI-H630 NUnFUmNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XFN2lEPTB;MU[uPFU{PyEQvF2= NH3OVHlUSU6JRWK=
KYSE-140 NVnoSFY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3CfVVsUUN3ME2xO{4zODJ6IN88US=> Ml3uV2FPT0WU
T84 NXjWOpdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHGZmtKSzVyPUG4Mlg3QTVizszN M2Lkb3NCVkeHUh?=
KU-19-19 M4HpWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3PTWM2OD1zOD65OlA5KM7:TR?= NIiwXXdUSU6JRWK=
BALL-1 MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPWTWM2OD1zOT6zN|k6KM7:TR?= M{\tcnNCVkeHUh?=
Calu-6 MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3ZZlhCUUN3ME2xPU41QTJizszN NUHYN45bW0GQR1XS
EGI-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33jTmlEPTB;MUmuOVk5KM7:TR?= M2jOW3NCVkeHUh?=
MFH-ino NGHF[5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrwTWM2OD1zOT63OFU1KM7:TR?= MlrnV2FPT0WU
GB-1 NWTqZ45wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LFeWlEPTB;MkCuN|U{PSEQvF2= MUjTRW5ITVJ?
NCI-H1693 MkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTJyLk[1NFUh|ryP NYHC[YtlW0GQR1XS
SW1116 NFPIeFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTHTWM2OD1{MD65N|YzKM7:TR?= M1HTc3NCVkeHUh?=
H-EMC-SS Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJ{LkC0OUDPxE1? MYHTRW5ITVJ?
D-502MG NI[wblJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJ{LkiyOlEh|ryP MVHTRW5ITVJ?
IA-LM MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\wTWM2OD1{Mz6yOFk{KM7:TR?= MorhV2FPT0WU
SW1463 M{LrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHkTWM2OD1{Mz63PUDPxE1? NIH4Zo9USU6JRWK=
JAR NHf1SW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nhV2lEPTB;MkSuN|I6OyEQvF2= M{PNfXNCVkeHUh?=
HT M3O1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXLfpVHUUN3ME2yOE41PzV|IN88US=> NWm1U25oW0GQR1XS
LCLC-103H Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fLUWlEPTB;MkSuPFQ1QSEQvF2= NYn0OXd4W0GQR1XS
SNU-449 NYjXW29UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTJ2Lki3OFEh|ryP M1XLbnNCVkeHUh?=
KE-37 M2G0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoW5TWM2OD1{NT6wPVI5KM7:TR?= M3faRXNCVkeHUh?=
NCI-H1623 NVTQXI9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33t[GlEPTB;MkeuNVMxOyEQvF2= MUXTRW5ITVJ?
MOLT-13 NWPROolST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfqSmZKSzVyPUK3MlM2OTZizszN M2nYfHNCVkeHUh?=
COLO-741 M4S3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTNzLkOzN|Mh|ryP MlLFV2FPT0WU
NB6 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXONIVSUUN3ME2zNk4zQDd4IN88US=> NWTSVXdOW0GQR1XS
MOLT-16 NFPq[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3zTWM2OD1|Mz6wNFU2KM7:TR?= NI[0Z2tUSU6JRWK=
IST-MES1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVm4cHNZUUN3ME2zOE4xPTRzIN88US=> MYLTRW5ITVJ?
A4-Fuk NG\6PIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzjOHkxUUN3ME2zOU4xPjZizszN M{PFfnNCVkeHUh?=
CAL-85-1 M1iwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmS5TWM2OD1|NT6yPFE4KM7:TR?= MWXTRW5ITVJ?
CCRF-CEM MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTN5LkG1N|Yh|ryP M16zSnNCVkeHUh?=
HAL-01 MkS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH1TWM2OD1|OD60PFg6KM7:TR?= MXPTRW5ITVJ?
HEL MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvyPIlFUUN3ME20N{4{PDB7IN88US=> MkPlV2FPT0WU
EW-1 M1;ZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\aUJNiUUN3ME20N{41PzZ6IN88US=> NEHlWGNUSU6JRWK=
MDA-MB-231 NX6yXIg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nxVmlEPTB;NEWuNVE6QSEQvF2= MYLTRW5ITVJ?
ABC-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nCUmlEPTB;NE[uPFU{QCEQvF2= NX3mZVJFW0GQR1XS
NCI-H446 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HVTGlEPTB;NEiuOVA2QCEQvF2= M17QS3NCVkeHUh?=
MHH-PREB-1 NVmzc5JET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfRd2dPUUN3ME20PU43ODB5IN88US=> NYnwfZB7W0GQR1XS
DOHH-2 M12wUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn[0TWM2OD12OT62OlU3KM7:TR?= NWC4OnJyW0GQR1XS
GCT MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHH6SZpKSzVyPUS5MlY6PzZizszN MmrOV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
α-Synuclein / HSP90 / HSP70 / HSP32 / αB-Crystallin; 

PubMed: 20090920     


Immunoblot analysis of heat shock protein induction. Cells were treated with 17-AAG (1–200 nM, 24 h), or subjected to heat shock (HS: 44°C, 30 min, 24 h recovery) or to MG-132 (MG: 1 µM, 24 h). Cell lysates were prepared and immunoblot analysis was carried out with antibodies against the individual proteins as indicated on the right. Co, untreated control.

EGFR / PDGFR / AKT / MAPK / c-RAS; 

PubMed: 18682579     


17-AAG promotes the degradation of HSP90 client proteins that are involved in the pathology of glioblastoma multiforme (GBM). Glioma cell lines were treated with increasing concentrations of 17-AAG for 48 h, and protein lysates were run on Western blots. HSP90 client proteins known to be involved in gliomagenesis showed degradation while nonclient proteins remained unaffected by 17-AAG treatment.

pAKT / pMAPK / pRb; 

PubMed: 18682579     


The phosphorylated states of signaling proteins involved in glioma growth are also affected by 17-AAG treatment.

Cleaved PARP / Survivin; 

PubMed: 18827603     


Western analysis of expression levels of cleaved PARP and Survivin in MM cell lines. β-Actin served as loading control.

LATS1 / p-LATS1 / YAP / CTGF; 

PubMed: 25712415     


Effects of 17-AAG on the expression of LATS1, p-LATS1, YAP and CTGF.  The expression levels of YAP and CTGF proteins, indicated by Western blot assay, were down-regulated, while LATS1 was upregulated in a dose-dependent manner in 17-AAG treated groups compared to the untreated group.

20090920 18682579 18827603 25712415
Immunofluorescence
STAT3; 

PubMed: 27279418     


Effects of 17-AAG on STAT3 expression of H446 cells. (A) Control group; (B) 3.125 mg/l; (C) 6.25 mg/l. 17-AAG, 17-allylamino-17-demethoxygel-danamycin; STAT3, signal transducer and activator of transcription 3; DAPI, 4′,6-diamidino-2-phenylindole.

YAP / TAZ; 

PubMed: 25290150     


Reduction in cytoplasmic distribution accompanied by increased nuclear localization of YAP/TAZ was more apparent in cells treated with 45 nM 17-AAG (red channel for YAP/TAZ and blue channel for nucleus). Statistical comparisons were performed using one-way Kruskal-Wallis multiple comparison, ***p<0.001 compared with control (0 nM).

β-catenin / E-cadherin; 

PubMed: 25290150     


Co-localization of β-catenin (Red) and E-cadherin (Green) was observed at the cell-cell junctions (white arrows) both in siCtrl and siCTGF cells after 17-AAG treatment. Scale bar is 20 µm.

27279418 25290150
Growth inhibition assay
Cell viability; 

PubMed: 18682579     


17-AAG inhibits the growth of human glioma cell lines. Human glioma cell lines and a nontumorigenic fibroblast cell line were treated with increasing concentrations of 17-AAG for 4 days, and the effect on cell growth was assessed by a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay. The 50% inhibitory concentration (IC50) of all glioma cell lines ranged from 0.05 to 0.5 μM 17-AAG, as compared to 1.5 μM for the nontumorigenic cells.

18682579
In vivo 17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. [1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. [2]

Protocol

Kinase Assay:[1]
- Collapse

Hsp90 binding assays:

Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl2, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:[1]
- Collapse
  • Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 5 days
  • Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A490) of wells not containing cells is subtracted. Percentage of viable cells = (A490 of 17-AAG treated sample/A490 untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6
  • Dosages: ~50 mg/kg
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (170.73 mM)
Water Insoluble
Ethanol '''5 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+corn oil
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 585.69
Formula

C31H43N3O8

CAS No. 75747-14-7
Storage powder
in solvent
Synonyms CP127374,NSC-330507, KOS 953
Smiles CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)C)OC)OC(=O)N)C)C)O)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00103272 Terminated Drug: tanespimycin|Drug: bortezomib Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia National Cancer Institute (NCI) April 2005 Phase 1
NCT00098488 Terminated Drug: tanespimycin|Biological: rituximab B-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Refractory Chronic Lymphocytic Leukemia National Cancer Institute (NCI) April 2005 Phase 1
NCT00118248 Completed Drug: tanespimycin Recurrent Thyroid Cancer|Stage IV Follicular Thyroid Cancer|Stage IV Papillary Thyroid Cancer|Thyroid Gland Medullary Carcinoma National Cancer Institute (NCI) December 2004 Phase 2
NCT00098423 Completed Drug: tanespimycin|Drug: cytarabine Accelerated Phase Chronic Myelogenous Leukemia|Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Blastic Phase Chronic Myelogenous Leukemia|Chronic Myelomonocytic Leukemia|de Novo Myelodysplastic Syndromes|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts in Transformation|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|Secondary Myelodysplastic Syndromes National Cancer Institute (NCI) November 2004 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?

  • Answer:

    17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (HSP90) Signaling Pathway Map

HSP (HSP90) Inhibitors with Unique Features

Related HSP (HSP90) Products

Tags: buy Tanespimycin (17-AAG) | Tanespimycin (17-AAG) supplier | purchase Tanespimycin (17-AAG) | Tanespimycin (17-AAG) cost | Tanespimycin (17-AAG) manufacturer | order Tanespimycin (17-AAG) | Tanespimycin (17-AAG) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID